These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25890430)

  • 1. Soy β-conglycinin improves obesity-induced metabolic abnormalities in a rat model of nonalcoholic fatty liver disease.
    Wanezaki S; Tachibana N; Nagata M; Saito S; Nagao K; Yanagita T; Kohno M
    Obes Res Clin Pract; 2015; 9(2):168-74. PubMed ID: 25890430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soy β-Conglycinin Peptide Attenuates Obesity and Lipid Abnormalities in Obese Model OLETF Rats.
    Wanezaki S; Saito S; Inoue N; Tachibana N; Shirouchi B; Sato M; Yanagita T; Nagao K
    J Oleo Sci; 2020; 69(5):495-502. PubMed ID: 32378551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soy β-conglycinin improves glucose uptake in skeletal muscle and ameliorates hepatic insulin resistance in Goto-Kakizaki rats.
    Tachibana N; Yamashita Y; Nagata M; Wanezaki S; Ashida H; Horio F; Kohno M
    Nutr Res; 2014 Feb; 34(2):160-7. PubMed ID: 24461318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary β-Conglycinin Modulates Insulin Sensitivity, Body Fat Mass, and Lipid Metabolism in Obese Otsuka Long-Evans Tokushima Fatty (OLETF) Rats.
    Kawabeta K; Hase-Tamaru S; Yuasa M; Suruga K; Sugano M; Koba K
    J Oleo Sci; 2019 Apr; 68(4):339-350. PubMed ID: 30867392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective Food Ingredients for Fatty Liver: Soy Protein β-Conglycinin and Fish Oil.
    Yamazaki T; Li D; Ikaga R
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30567368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of β-conglycinin on renal function and nephrin expression in early streptozotocin-induced diabetic nephropathy rats.
    Yang HY; Wu LY; Yeh WJ; Chen JR
    Br J Nutr; 2014 Jan; 111(1):78-85. PubMed ID: 23803175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soybean beta-conglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of beta-oxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption.
    Moriyama T; Kishimoto K; Nagai K; Urade R; Ogawa T; Utsumi S; Maruyama N; Maebuchi M
    Biosci Biotechnol Biochem; 2004 Feb; 68(2):352-9. PubMed ID: 14981298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum lipid-improving effect of soyabean β-conglycinin in hyperlipidaemic menopausal women.
    Ma D; Taku K; Zhang Y; Jia M; Wang Y; Wang P
    Br J Nutr; 2013 Nov; 110(9):1680-4. PubMed ID: 23561330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soya protein β-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPARγ.
    Li D; Ikaga R; Yamazaki T
    Br J Nutr; 2018 Jun; 119(11):1220-1232. PubMed ID: 29770757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary β-conglycinin prevents fatty liver induced by a high-fat diet by a decrease in peroxisome proliferator-activated receptor γ2 protein.
    Yamazaki T; Kishimoto K; Miura S; Ezaki O
    J Nutr Biochem; 2012 Feb; 23(2):123-32. PubMed ID: 21447441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The α' subunit of β-conglycinin and various glycinin subunits of soy are not required to modulate hepatic lipid metabolism in rats.
    Chatterjee C; Liu J; Wood C; Gagnon C; Cober ER; Frégeau-Reid JA; Gleddie S; Xiao CW
    Eur J Nutr; 2018 Apr; 57(3):1157-1168. PubMed ID: 28324208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.
    Ferreira ES; Silva MA; Demonte A; Neves VA
    Lipids Health Dis; 2012 Jan; 11():11. PubMed ID: 22243700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-conglycinin lowers very-low-density lipoprotein-triglyceride levels by increasing adiponectin and insulin sensitivity in rats.
    Tachibana N; Iwaoka Y; Hirotsuka M; Horio F; Kohno M
    Biosci Biotechnol Biochem; 2010; 74(6):1250-5. PubMed ID: 20530915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats.
    Panasevich MR; Schuster CM; Phillips KE; Meers GM; Chintapalli SV; Wankhade UD; Shankar K; Butteiger DN; Krul ES; Thyfault JP; Rector RS
    J Nutr Biochem; 2017 Aug; 46():125-136. PubMed ID: 28605664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective and reparative effects of peptides from soybean β-conglycinin on mice intestinal mucosa injury.
    Ren J; Yang B; Lv Y; Guo S
    Int J Food Sci Nutr; 2014 May; 65(3):345-50. PubMed ID: 24224901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary β-conglycinin prevents acute ethanol-induced fatty liver in mice.
    Ikaga R; Li D; Yamazaki T
    Biochem Biophys Res Commun; 2017 Nov; 493(1):542-547. PubMed ID: 28867186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soy β-conglycinin retards progression of diabetic nephropathy via modulating the insulin sensitivity and angiotensin-converting enzyme activity in rats fed with high salt diet.
    Yeh WJ; Yang HY; Chen JR
    Food Funct; 2014 Nov; 5(11):2898-904. PubMed ID: 25205218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of soybean beta-conglycinin on hepatic lipid metabolism and fecal lipid excretion in normal adult rats.
    Fukui K; Kojima M; Tachibana N; Kohno M; Takamatsu K; Hirotsuka M; Kito M
    Biosci Biotechnol Biochem; 2004 May; 68(5):1153-5. PubMed ID: 15170126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.
    Linden MA; Lopez KT; Fletcher JA; Morris EM; Meers GM; Siddique S; Laughlin MH; Sowers JR; Thyfault JP; Ibdah JA; Rector RS
    Appl Physiol Nutr Metab; 2015 Oct; 40(10):1038-47. PubMed ID: 26394261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.